ZIOPHARM to Present at the 18th Annual BIO CEO & Investor Conference
February 02 2016 - 7:00AM
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that
Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present
at the 18th Annual BIO CEO & Investor Conference on Tuesday,
February 9th, 2016 at 1:00 p.m. ET. The conference is being held at
the Waldorf Astoria Hotel in New York City.
To access a live audio webcast of the
presentation, please visit the Investor Relations section
at www.ziopharm.com. The webcast will be archived for 90
days.
About ZIOPHARM Oncology,
Inc.:
ZIOPHARM Oncology is a Boston,
Massachusetts-based biotechnology company employing novel gene
expression, control and cell technologies to deliver safe,
effective and scalable cell- and viral-based therapies for the
treatment of cancer. The Company's synthetic immuno-oncology
programs, in collaboration with Intrexon Corporation (NYSE:XON) and
the MD Anderson Cancer Center, include chimeric antigen receptor T
cell (CAR-T) and other adoptive cell based approaches that use
non-viral gene transfer methods for broad scalability. The Company
is advancing programs in multiple stages of development together
with Intrexon Corporation's RheoSwitch Therapeutic System®
technology, a switch to turn on and off, and more precisely
modulate gene expression in order to improve therapeutic index. The
Company's pipeline includes a number of cell-based therapeutics in
both clinical and preclinical testing which are focused on
hematologic and solid tumor malignancies.
Contact:
Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
locchiogrosso@ziopharm.com
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
Intrexon (NASDAQ:XON)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intrexon (NASDAQ:XON)
Historical Stock Chart
From Sep 2023 to Sep 2024